Thanks for the reminder of study description Bear.

This is good news regardless. Even so, here are some of my worst-case conerns:

We have been reading and hoping that Apabetalone may prevent long term organ damage in covid patients.  That population is a subset of a subset, but an important one.

Clearly, this trial as described may be too short to really answer that  specific question.

If, as has happened in past, Apabetalone fails to meet its primary target, whether due  powering, time frame, or just being better at something else...its true potential could still exist in terns of addressing long term damage issues, but remain unrecognized. 

Then what? Game over?

And... even if it succeeds,  (not really worst case at all, but still) do the patients stop taking it after 4 weeks? Do we know that dose term is long enough for true prevention/healing of potential organ damage in vivo? What if stopping too soon reduces protective effect, before damage risk has fully cleared? We could still have no clear answer re:long term damage?

And in these worst-case scenarios, what happens to BETonMACE, given our finances?